Sign In
Buy BAYRY
$9.92
+0.0400 (+0.405%)
At Close: Jun 03, 2026
Bayer's Pharma Growth Strategy Progressing Well as Pipeline Advances
01:30pm, Tuesday, 14'th Jan 2025
WHIPPANY, N.J.--(BUSINESS WIRE)--On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple
Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Copper Ammonium Carbonate Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering. The copper ammonium carbonate
Bayer pharma chief sees no big acquisitions in near future
02:23am, Tuesday, 14'th Jan 2025
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an interview published on Tue
Bayer's investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
11:22am, Friday, 10'th Jan 2025
BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an in
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for KERENDIA® (finerenone) for the t
Orion's collaboration partner Bayer submits application in China for third indication of darolutamide
02:00am, Tuesday, 07'th Jan 2025
ORION CORPORATION INVESTOR NEWS 7 JANUARY 2025 at 9:00 EET Orion's collaboration partner Bayer submits application in China for third indication of darolutamide Orion's collaboration
Bayer: Federal Court Brings an End to Roundup™ Litigation in Australia
08:54am, Friday, 03'rd Jan 2025
LEVERKUSEN, Germany--(BUSINESS WIRE)--The Federal Court of Australia brought an end to the last Roundup™ case in Australia, closing all pending injury litigation there. The Court granted the plainti
Bayer Partners with America's Grow-A-Row to Aid in the Fight Against Hunger in New Jersey
08:10am, Tuesday, 17'th Dec 2024
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced the successful completion of its fall employee engagement campaign with America's Grow-a-Row (AGAR), a New Jersey-based, nonprofit farm where approxima
Bayer's Stock Hits 2-Decade Low: Why It Is A Buy Again
03:08am, Friday, 06'th Dec 2024
Bayer's stock has declined below €20, with Q3/24 results showing a 3.6% sales decrease and a 29.8% EBITDA drop, mainly due to currency effects. Crop Science sales fell 9.1% YoY, and Pharmaceuticals
Bayer Showcases Growing Radiology Portfolio at RSNA 2024
10:10am, Sunday, 01'st Dec 2024
CHICAGO--(BUSINESS WIRE)--Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline as well as innovations around Artificial Intelligence (AI) and will
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Watermelon Seeds Market Size, Share & Trends Analysis Report by Type (Raw, Roasted, Dried), Distribution Channel, Region and Segment Forecasts, 2025-2030
FDA Accepts Bayer's Application for Label Expansion of Nubeqa
02:41pm, Friday, 22'nd Nov 2024
Bayer's efforts to expand Nubeqa's label in prostate cancer make progress with the FDA's acceptance of the company's sNDA.
Bayer Announces ‘Project Enhanced S3' to Enable Companies to Realize Additional Sustainability Value from Carbon Removal Projects
09:00am, Thursday, 21'st Nov 2024
ST. LOUIS--(BUSINESS WIRE)--Bayer announced today an expanded approach to its programs that sequester carbon and reduce emissions for companies along the food value chain through regenerative agricult
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
10:31am, Wednesday, 20'th Nov 2024
BAYRY enters into a collaboration and license agreement with Cytokinetics for the exclusive development and commercialization of aficamten in Japan.
Bayer acquires rights to Cytokinetics' heart drug in Japan
03:26am, Tuesday, 19'th Nov 2024
Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group strengthens its cardiovascular bu
